The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | A retrospective study analyzing outcomes of patients with anti-CD38 refractory myeloma
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines results from a retrospective analysis which evaluated the outcomes of patients with multiple myeloma who relapsed or progressed on anti-CD38 monoclonal antibodies. Prof. Kastritis believes that combined therapy with anti-CD38 agents could be a beneficial approach until novel treatment options emerge. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
